

## Basic science: (October 2008)

1. Beetstra S, Suthers G, Dhillon V, Salisbury C, Turner J, Altree M, McKinnon R, Fenech M. Methionine-dependence phenotype in the de novo pathway in *BRCA1* and *BRCA2* mutation carriers with and without breast cancer. *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 2565–2571.
2. Bempt IV, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, Paridaens R, De Wolf-Peeters C. Polysomy 17 in breast cancer: clinicopathologic significance and impact on *HER-2* testing. *J Clin Oncol* 2008; **26**: 4869–4874.
3. Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, Lindeman GJ, Visvader JE. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. *Cell Stem Cell* 2008; **3**: 429–441.
4. Castro-Rivera E, Ran S, Brekken RA, Minna JD. Semaphorin 3B inhibits the Phosphatidylinositol 3-Kinase/Akt Pathway through Neuropilin-1 in lung and breast cancer cells. *Cancer Res* 2008; **68**: 8295–8303.
5. Conzen SD. Nuclear receptors and breast cancer. *Mol Endocrinol* 2008; **22**: 2215–2228.
6. Davis VL, Jayo MJ, Ho A, Kotlarczyk MP, Hardy ML, Foster WG, Hughes CL. Black Cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2. *Cancer Res* 2008; **68**: 8377–8383.
7. DuSell CD, McDonnell DP. 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling. *Trends Pharmacol Sci* 2008; **29**: 510–514.
8. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA. Hormone therapy and the risk of breast cancer in *BRCA1* mutation carriers. *J Natl Cancer Inst* 2008; **100**: 1361–1367.
9. Ellis MJ, Tao Y, Luo JQ, A'Hern R, Evans DB, Bhatnagar AS, Ross HAC, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. *J Natl Cancer Inst* 2008; **100**: 1380–1388.
10. Fabre A, Fournier A, Mesrine S, Gompel A, Desreux J, Berrino F, Boutron-Ruault MC, Romieu I, Clavel-Chapelon F. Progestagens use before menopause and breast cancer risk according to histology and hormone receptors. *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 2723–2728.
11. Firlej V, Ladam F, Brysbaert G, Dumont P, Fuks F, de Launoit Y, Benecke A, Chotteau-Lelievre A. Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription. *J Cell Sci* 2008; **121**: 3393–3402.
12. Gaudet MM, Chanock S, Dunning A, Driver K, Brinton LA, Lissowska J, Peplonska B, Pharoah P, Garcia-Closas M. *HSD17B1* genetic variants and hormone receptor-defined breast cancer. *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 2766–2772.
13. Ginsburg OM, Martin LJ, Boyd NF. Mammographic density, lobular involution, and risk of breast cancer. *Br J Cancer* 2008; **99**: 1369–1374.
14. Green CA, Peter MB, Speirs V, Shaaban AM. The potential role of ER  $\beta$  isoforms in the clinical management of breast cancer. *Histopathology* 2008; **53**: 374–380.
15. Guerra E, Trerotola M, Dell'Arciprete R, Bonasera V, Palombo B, El-Sewedy T, Ciccimarra T, Crescenzi C, Lorenzini F, Rossi C, Vacca G, Lattanzio R, Piantelli M, Alberti S. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. *Cancer Res* 2008; **68**: 8113–8121.
16. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? *Bioinformatics* 2008; **24**: 2200–2208.
17. Howe LR, Lippman SM. Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. *J Natl Cancer Inst* 2008; **100**: 1420–1423.

18. Hwang KT, Han W, Cho J, Lee JW, Ko E, Kim EK, Jung SY, Jeong EM, Bae JY, Kang JJ, Yang SJ, Kim SW, Noh DY. Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. *Int J Cancer* 2008; **123**: 1807–1815.
19. John S, Nayvelt I, Hsu HC, Yang PA, Liu WS, Das GM, Thomas T, Thomas TJ. Regulation of estrogenic effects by Beclin 1 in breast cancer cells. *Cancer Res* 2008; **68**: 7855–7863.
20. Kabil A, Silva E, Kortenkamp A. Estrogens and genomic instability in human breast cancer cells – involvement of Src/Raf/Erk signaling in micronucleus formation by estrogenic chemicals. *Carcinogenesis* 2008; **29**: 1862–1868.
21. Katsuno Y, Hanyu A, Kanda H, Ishikawa Y, Akiyama F, Iwase T, Ogata E, Ehata S, Miyazono K, Imamura T, . Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. *Oncogene* 2008; **27**: 6322–6333.
22. Kavanagh AM, Byrnes GB, Nickson C, Cawson JN, Giles GG, Hopper JL, Gertig DM, English DR. Using mammographic density to improve breast cancer screening outcomes. *Cancer Epidemiol Biomarkers Prev* 2008; **17**: 2818–2824.
23. Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S, Sjoblom T, Park BH, Parsons R, Willis J, Dawson D, Willson JKV, Nikolskaya T, Nikolsky Y, Kopelovich L, Papadopoulos N, Pennacchio LA, Wang TL, Markowitz SD, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. *Proc Natl Acad Sci USA* 2008; **105**: 16224–16229.
24. Liapis E, McLuckie KIE, Lewis PD, Farmer PB, Brown K. Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots. *Nucleic Acids Res* 2008; **36**: 5933–5945.
25. Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD, Gao YT, Zheng W, Colditz GA. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. *J Natl Cancer Inst* 2008; **100**: 1352–1360.
26. Marlow R, Strickland P, Lee JS, Wu XY, PeBenito M, Binnewies M, Le EK, Moran A, Macias H, Cardiff RD, Sukumar S, Hinck L. SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium. *Cancer Res* 2008; **68**: 7819–7827.
27. Mazan-Mamczarz K, Hagner PR, Dai BJ, Wood WH, Zhang YQ, Becker KG, Liu ZQ, Gartenhaus RB. Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach. *Cancer Res* 2008; **68**: 7730–7735.
28. Miller JK, Shattuck DL, Ingalla EQ, Yen LL, Borowsky AD, Young LJT, Cardiff RD, Carraway KL, Sweeney C. Suppression of the negative regulator *LRIG1* contributes to *ErbB2* overexpression in breast cancer. *Cancer Res* 2008; **68**: 8286–8294.

Prepared by  
R Sutherland  
Cancer Research Program  
Garvan Institute of Medical Research  
Darlinghurst, NSW, Australia